Role of endothelin in preeclampsia and hypertension following antiangiogenesis treatment.
Rotterdam, Netherlands. In Curr Opin Nephrol Hypertens, Jan 2016
Administration of endothelin receptor A-selective or dual endothelin receptor antagonists can prevent or largely attenuate the hypertension and proteinuria in experimental forms of preeclampsia, as well as in rats exposed to receptor tyrosine-kinase inhibitors targeting VEGF-signaling, supporting the concept that activation of the endothelin axis plays a key role in the manifestations of these disorders.
Improvements in the Management of Diabetic Nephropathy.
Ioánnina, Greece. In Rev Diabet Stud, 2014
Novel agents, such as bardoxolone methyl, pentoxifylline, inhibitors of protein kinase C (PKC), sulodexide, pirfenidone, endothelin receptor antagonists, vitamin D supplements, and phosphate binders have been associated with controversial outcomes or significant side effects.
The pharmacological treatment of pulmonary arterial hypertension.
In Pharmacol Rev, 2012
Advances in understanding the pathobiology over the last 2 decades have led to therapies (endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclins or analogs) initially directed at reversing the pulmonary vasoconstriction and more recently directed toward reversing endothelial cell dysfunction and smooth muscle cell proliferation.